retatrutide nejm 2023 obesity trial ly3437943 phase 2 The that put “24%” on the map 💉 A triple-action once-weekly injection – Results from a new trial

Novo Nordisk aims to utilize the TransCon platform to develop and commercialize metabolic therapeutics for obesity and Type 2 diabetes

Therapeutically, it modulates immune responses and, when combined with Bifidobacterium bifidum , significantly reduces the incidence of rotavirus-induced gastroenteritis in pediatric populations

doi: 10.3389/fimmu.2025.1709561 Received 20 September 2025 Revised 16 October 2025 Accepted 11 November 2025 Published 26 November 2025 Volume 16 - 2025 Edited by Juan Pablo de Rivero Vaccari, University of Miami, United States Reviewed by Emir Malovic, University of Illinois Chicago, United States Anna Maria Sardanelli, University of Bari Aldo Moro, Italy Updates Copyright 2025 Tu, Han, Zhang, Jia, Sun, Liu, Li, Tang and Wang

Dietary exposure to 2, 2, 4, 4-tetrabromodiphenyl ether (PBDE-47) alters thyroid status and thyroid hormone-regulated gene transcription in the pituitary and brain

If you have a different lifestyle, and you only want to do keto or you want to do veggie, thats already there for you